**Core tip:** Crohn's disease (CD) diagnoses are increasing in Asia. While family history of inflammatory bowel disease (IBD) is recognized as the strongest independent risk factor for CD in western populations, it is unknown if family history plays a role in Asians. This study compares the prevalence of IBD family history, the relationships of affected relatives, and CD-related outcomes such as ileal involvement, surgery, and medication use between China and the United States.

INTRODUCTION
============

Crohn's disease (CD) is a form of inflammatory bowel disease (IBD), featured by chronic inflammation, most frequently affecting the terminal ileum and colon, but can also involve other portions of the gastrointestinal (GI) tract from mouth to anus\[[@B1]\]. The first mention of CD appeared in the literature in 1932 in a publication by Burrill Crohn reporting on a subacute or chronic necrotizing and cicatrizing inflammatory disease of the terminal ileum affecting mainly young adults in New York city\[[@B2]\]. Incidence rates of CD were first published in 1965, reporting an estimated 1.3 cases per 100000 person-years during 1955 to 1963 in Scotland\[[@B3]\]. Since then, the incidence rate of CD in western countries has shown a significant increasing trend, and the annual incidence rates between 1991 to 2008 were estimated to range from 10.6 to 29.3 per 100000 in North America, Europe, and Australia\[[@B4]\]. In contrast, the CD incidence rate in Asia was first published in 1974, reporting 0.04 cases per 100000 person-years in Singapore during 1965-1970\[[@B5]\]. Similar to western countries, the incidence of CD has increased over time. The estimated annual CD incidence rate (per 100000 person-years) based on population-based longitudinal cohorts in Hong Kong\[[@B6]\], Japan\[[@B7]\], and South Korea\[[@B8]\] has increased from 0.1-0.6 in 1986-1992 to 1.0-1.3 in 1998-2005.

In China, CD was first documented in the literature in 1960s and the incidence is assumed to be increasing based on single hospital-based studies. The current estimated incidence is 0.1 to 1.3 cases per 100000 person-years\[[@B9]\]. The proposed increase in incidence has been attributed to environmental exposures, such as industrialization and urbanization of the society, westernization of lifestyle and dietary habits, because of the parallelism of their occurrence\[[@B4],[@B10],[@B11]\].

The lower incidence of CD may be due in part to differences in genetic risk factors. Polymorphisms of the *NOD2*/*CARD15* gene have been found to account for up to 20% of CD in Caucasian\[[@B12]\] populations\[[@B13]\], but there have not been consistent findings of such association in China\[[@B14]-[@B17]\].

Family history is a window to both the genetic background and shared environment. Having a relative with IBD is the strongest known risk factor for developing CD in western countries\[[@B18]\]. However, family history of IBD among Chinese CD patients has not been studied in detail. Thirteen hospital-based studies reported the prevalence of family history of IBD (any affected family member) among Chinese CD patients to be 0% to 4.5%, although the details on the relations of family members are not known\[[@B6],[@B19]-[@B29]\]. In contrast, 8% to 25% of CD patients in western countries have a blood relative with IBD\[[@B30],[@B31]\], and 8% to 14.5% of CD patients have a first-degree relative with IBD\[[@B18],[@B31]\].

Clinical characteristics and complication rates differ among Asians with CD. A systematic review of 151 studies suggested Asian CD patients are more likely to be male, with a higher prevalence of ileocolonic involvement and lower surgical rates than Western estimates\[[@B29],[@B32]\].

We hypothesized that there would be differences in family history of IBD and clinical outcomes between CD patients in China and the United States. We targeted three aims to address our hypothesis. The first was to investigate and compare the prevalence of family history of IBD among CD patients in China and the United States. The second was to examine the distribution of relationships of the affected relatives. Third, we aimed to study the difference in prevalence of CD outcomes including ileal involvement, CD-related surgeries and use of medications.

MATERIALS AND METHODS
=====================

Study population
----------------

Patients were recruited from one source in China and two sources in the United States. In China, patients with CD seen by gastroenterologists at the IBD clinic of the 6^th^ Affiliated Hospital of Sun Yat-sen University (SYSU), Guangdong, China, during a clinic visit from May 2014 to December 2015. This hospital is a referral center for IBD patients in the Guangdong area. In the United States, patients were recruited at Johns Hopkins University-affiliated clinics or through the participant recruitment website ResearchMatch (RM). RM is a disease-neutral, institution-neutral, online volunteer recruitment platform designed to match volunteers with researchers\[[@B33]\]. The Johns Hopkins participants were recruited by email, letter, flyer, or during a clinic visit between May 2015 and February 2016. Individuals who indicated that they had IBD on their ResearchMatch profiles were recruited *via* email from May 2015 to February 2016.

In China, participants were administered a survey by face-to-face interview with a healthcare professional. In the United States participants completed the survey online (bit.ly/IBD-MIMAS). The survey was created and administered using the REDCap\[[@B34]\] project hosted at Johns Hopkins University. The survey included questions about demographics, timing of CD diagnosis, disease location and treatment history, family history of IBD and relationship, age at diagnosis of IBD type of the affected family members (Appendix tables). Participants were included in the analysis only if they completed the family history and disease outcome modules of the survey and were aged 18 years or older at the time of survey completion. Individuals with unknown family history were excluded (1 individual from the United States who was adopted).

IBD family history assessment
-----------------------------

Family history of IBD was classified using self-reported information on the survey. Questions were asked regarding knowledge of any family history, details on the number of relatives affected, as well as the relationship to the participant (Appendix Table 2). Any family history of IBD was defined as having one or more blood relatives diagnosed with any type of IBD. For participants who had any family history of IBD, they were further subdivided as having first-degree relative family history if they had at least one parent, sibling or child with IBD.

Crohn's disease related outcomes assessment
-------------------------------------------

The primary clinical outcome was ileal involvement. History of ileal involvement was determined by self-report (Appendix Table 3). Secondary outcomes included self-reported history of CD-related surgery, and ever use of IBD-related medications including steroids, immunomodulators, and biologics (Appendix Table 4).

Potential confounding factors
-----------------------------

Participants self-reported sex, date of birth, date of CD diagnosis, number of siblings, number of children, and smoking status at CD diagnosis (Appendix Tables 1 and 2). Duration of disease was defined as the period of time from the date of clinical diagnosis to the date of survey completion. Smoking status at the time of diagnosis was categorized as current, former, and never smoker. Participants with more family members and longer disease duration are more likely to have a family member with IBD and the family size and duration of disease differed between countries making these factors potential confounders. Similarly, individuals with longer disease duration had greater potential to have ileal disease detected or medication changes.

Statistical analysis
--------------------

We compared the demographic differences between China and the United States using frequencies for categorical variables and median and range for continuous variables. Frequency distributions were compared using Fisher's exact tests and medians were compared with Mood's median tests. We created a figure similar to a pedigree but for the entire population to examine the familial relationships between countries. We used multivariable logistic regression models to compare the prevalence of family history between China and the United States, adjusting for the total number of siblings and children and the duration of disease at the time of survey. We used separate multivariable logistic regression models to compare the difference in the outcomes between countries adjusting for sex, smoking status at CD diagnosis, age at diagnosis older than 40 years *vs* less, and disease duration. We conducted all the statistical analysis in SAS^®^ 9.4 (SAS Institute Inc., Cary, NC, United States).

RESULTS
=======

Patient demographics
--------------------

We included 194 individuals with CD, 49 from China and 145 from the United States (Table [1](#T1){ref-type="table"}). In the United States, 111 were recruited from the academic center and 34 from ResearchMatch. Similarities between the two countries included a median age of approximately 26 years at diagnosis and a similar median number of siblings and children. Differences between the two countries included those from China were more likely to be male; had a younger age at diagnosis and age at the time of survey completion; and were diagnosed more recently.

###### 

Demographics of Crohn's disease patients in China and the United States recruited 2014-2016

                                               **China (*n* = 49)**   **United States (*n* = 145)**           ***P* value**
  -------------------------------------------- ---------------------- --------------------------------------- ---------------
  Age at clinical diagnosis (yr)               26.6 (13.1-46.7)       25.9 (5.1-73.1)                         0.87
  Age at survey completion (yr)                29.5 (19.2-49.9)       43.4 (18.3-82.7)                        \< 0.0001
  Duration of disease at time of survey (yr)   2.2 (0.0-12.7)         12.4 (0.0-55.4)                         \< 0.0001
  Calendar year of diagnosis                   2013 (2003-2015)       2003 (1960-2015)                        \< 0.0001
  Before 1969                                  0                      1.4%                                    
  1970-1979                                    0                      6.2%                                    
  1980-1989                                    0                      9.7%                                    
  1990-1999                                    0                      25.5%                                   
  2000-2009                                    12.2%                  30.3%                                   
  2010-2015                                    87.8%                  26.9%                                   
  Female (%)                                   42.9%                  58.6%                                   0.06
  Smoking status at diagnosis (%)                                                                             0.5
  Current smoker                               12.2%                  16.5%[1](#T1FN1){ref-type="table-fn"}   
  Former smoker                                6.1% (*n* = 3)         10.8%                                   
  Never smoker                                 81.6%                  72.7%                                   
  Number of siblings                           2 (0-7)                2 (0-9)                                 0.2
  0                                            8.2% (*n* = 4)         6.9%                                    
  1                                            12.2%                  29.7%                                   
  2                                            44.9%                  30.3%                                   
  3                                            12.2%                  18.6%                                   
  4+                                           22.5%                  14.5%                                   
  Number of children                           0 (0-3)                0 (0-7)                                 0.81
  0                                            53.1%                  51.0%                                   
  1                                            26.5%                  15.9%                                   
  2                                            18.4%                  22.8%                                   
  3                                            2.0% (*n* = 1)         9.0%                                    
  4+                                           0                      1.3%                                    

Six participants recruited in the United States did not report smoking status at diagnosis.

Family history of IBD
---------------------

After adjusting for duration of disease at the time of survey and the total number of relatives, the difference in family history was statistically significant. The prevalence of any family history of IBD was markedly lower in China than the United States (China: 4.1% *vs* United States: 39.3%, adjusted *P* = 0.0008, Table [2](#T2){ref-type="table"}). Family history of IBD in first-degree relatives was also less prevalent in China than in the United States (China: 4.1% *vs* United States: 23.5%, adjusted *P* = 0.01). Only two participants in China had a family history of IBD. Both had a first-degree relative affected (Figure [1](#F1){ref-type="fig"}).

###### 

Prevalence and odds ratio of having family history of inflammatory bowel disease in China *vs* the United States

                                           **China** **(*n* = 49)**   **United States** **(*n* = 145)**   **Unadjusted OR (95%CI) *P* value (Reference = US)**   **Adjusted[1](#T2FN1){ref-type="table-fn"} OR (95% CI) *P* value (Reference = US)**
  ---------------------------------------- -------------------------- ----------------------------------- ------------------------------------------------------ -------------------------------------------------------------------------------------
  Any family history of IBD (%)            4.1% (*n* = 2)             39.3%                               0.07 (0.02-0.28)                                       0.08 (0.02-0.34)
  *P* = 0.0002                             *P* = 0.0008                                                                                                          
  First-degree family history of IBD (%)   4.1% (*n* = 2)             23.5%                               0.14 (0.03-0.60)                                       0.14 (0.03-0.65)
  *P* = 0.008                              *P* = 0.01                                                                                                            

Adjusted for the total number of siblings and children, and duration of disease at survey completion. IBD: Inflammatory bowel disease; OR: Odds ratio.

![Relationship map of relatives with inflammatory bowel disease to patients with Crohn's disease in China and the United States.](WJGPT-7-556-g001){#F1}

For participants who reported any family history of IBD, the distribution of relationships of affected relatives was significantly different (Figure [1](#F1){ref-type="fig"}). For the two patients who had family history of IBD in China, one had a sibling affected and the other a child. In the United States, the mean number of affected relatives was 1.6 (median 1, maximum 5). The most commonly affected types of relatives were cousin (41.1%), sibling (37.5%), and parent (28.6%).

Disease outcomes
----------------

Participants from the two countries had equally high prevalence of ileal involvement (China: 63.3% *vs* United States: 63.5%, adjusted *P* = 0.74) and surgery (China: 51.0% *vs* United States: 49.7%, adjusted *P* = 0.19; Table [3](#T3){ref-type="table"}). Compared with the United States, the percentage of participants that had ever used steroids or a biologic was significantly lower in China. The difference in the use of immunomodulators was of borderline statistical significance with China having greater use than the United States (China: 73.5%, United States: 61.4%, adjusted *P* = 0.08).

###### 

Prevalence and odds ratio of Crohn's disease outcomes in China *vs* the United States

  **Outcome**                                             **China** **(*n* = 49)**   **United States** **(*n* = 145)**   **Unadjusted OR (95%CI), *P* value (Reference = US)**   **Adjusted[1](#T3FN1){ref-type="table-fn"} OR (95%CI), *P* value (Reference = US)**
  ------------------------------------------------------- -------------------------- ----------------------------------- ------------------------------------------------------- -------------------------------------------------------------------------------------
  Ileal involvement                                       63.3%                      63.5%                               0.99 (0.50-1.94)                                        1.14 (0.51-2.55)
  *P* = 0.98                                              *P* = 0.74                                                                                                             
  Surgery for IBD                                         51.0%                      49.7%                               1.06 (0.55-2.02)                                        1.70 (0.77-3.75)
  *P* = 0.87                                              *P* = 0.19                                                                                                             
  Ever steroids use                                       46.9%                      91.0%                               0.09 (0.04-0.19)                                        0.19 (0.07-0.50)
  *P* \< 0.0001                                           *P* = 0.0007                                                                                                           
  Steroids use within 3 mo of diagnosis                   24.5%                      46.2%                               0.38 (0.18-0.78)                                        0.53 (0.22-1.25)
  *P* = 0.009                                             *P* = 0.15                                                                                                             
  Ever immunomodulators[2](#T3FN2){ref-type="table-fn"}   73.5%                      61.4%                               1.74 (0.85-3.57)                                        2.13 (0.92-4.91)
                                                          (*n* = 36)                 (*n* = 89)                          *P* = 0.13                                              *P* = 0.08
  6-MP/Azathioprine                                       88.9%                      89.9%                                                                                       
  Methotrexate                                            19.4%                      23.6%                                                                                       
  Cyclosporine                                            0%                         6.7%                                                                                        
  Tacrolimus                                              0%                         3.4%                                                                                        
  Ever biologics use                                      34.7%                      73.8%                               0.19 (0.09-0.38)                                        0.09 (0.04-0.24)
  *P* \< 0.0001                                           *P* \< 0.0001                                                                                                          
  Ever TPN use                                            8.2%                       21.4%                               0.33 (0.11-0.98)                                        0.67 (0.19-2.38)
  *P* = 0.05                                              *P* = 0.54                                                                                                             
  Antibiotics use within 30 d before time of survey       18.8%                      15.9%                               1.22 (0.52-2.87)                                        1.29 (0.47-3.55)
  *P* = 0.64                                              *P* = 0.62                                                                                                             

Adjusted for sex, smoking status at diagnosis, age at diagnosis older than 40 years or less, and duration of disease at survey completion;

For ever users of immunomodulators, the percentage of use of each type of immunomodulators was calculated. IBD: Inflammatory bowel disease; 6-MP: Mercaptopurine; TPN: Total parenteral nutrition; OR: Odds ratio.

DISCUSSION
==========

The prevalence of family history of IBD and CD related clinical outcomes were different in China and the United States. The probability that CD patients from China had any blood relative affected with IBD was only 1/10 that of the United States CD patients, despite both patient populations coming from academic medical centers with dedicated IBD clinics. The percentage of CD patients in China who had first-degree relative affected with IBD was 1/6 that of the United States. Despite the differences in family history, the two countries shared high prevalence of ileal involvement and surgical history for IBD. However, CD patients in China were less likely to have ever used steroids and biologics but more likely to use immunomodulators, which might reflect differences in access to medications or practice variation.

Both the Chinese and the US estimates of family history prevalence are high compared with other studies. One possible reason is that the recruitment sites have dedicated IBD clinics with large numbers of patients referred by outside providers often because of greater disease severity, which might be associated with genetic predisposition. The higher estimates could also be due to the difference in ascertainment methods of family history. We ascertained family history through self-report on a questionnaire instead of obtaining information from physicians' notes in medical records. We believe that self-report might be able to capture more accurate information on detailed family history than medical records.

There has been much interest in investigating the characteristics of CD in Asian and western countries, but CD patients in China and the US have rarely been compared. Luo et al\[[@B29]\] compared family history of 85 Chinese and 68 American patients based on information obtained from medical records. They concluded Chinese CD patients had lower prevalence of CD family history than Americans (China 1% *vs* United States 12%, *P* = 0.016). One strength of our study was that we used the same questionnaire in both settings (available in English and Mandarin after back-translation confirmation) to ascertain family history during the same time period. In the comparison of family history prevalence, we adjusted for confounders such as patient's disease duration and family size.

We analyzed the distribution of relationships of affected relatives, which was rarely reported in previous studies in China. Although no individuals from China reported a cousin with IBD, this was the most commonly affected relative type in the United States. This finding could point to shared environmental risk between cousins and cases that could be explored further, especially among the Chinese CD participants as diagnoses of IBD are expected to increase in the coming years.

More than half of CD patients in both China and the United States had history of ileal involvement and about half had undergone surgeries to treat CD. This implies that CD patients of the two countries had similar severity of disease despite differences in family history and duration of disease. In contrast, Luo et al\[[@B29]\] found Chinese CD patients had significantly lower odds of having ileocaecum involvement compared with Americans. We were not able to examine the association of IBD family history and CD outcome by country in the present study, because the small number of individuals with IBD family history in China (*n* = 2) limited this analysis.

CD patients in China were less likely to have used steroids or biologics than those in the United States. Prideaux et al\[[@B23]\] had a similar finding when comparing steroid use at diagnosis and ever use of biologics between CD patients in Melbourne *vs* those in Hong Kong (steroids: Hong Kong 37.0% *vs* Melbourne 61.2%, *P* \< 0.001; anti-tumor necrosis factor therapy: Hong Kong 11.0% *vs* Melbourne 39.9%, *P* \< 0.001). This could be due to either real difference in the needs for steroids treatment or difference in physicians' practicing patterns. These same reasons could explain the differences in biologic use with the additional facts that biologics were introduced into China market later than the United States (2007 *vs* 1999), that only infliximab is currently available, and that most Chinese patients pay out of pocket at the United States equivalent rates limiting the population that has access to these drugs.

In conclusion, the lower prevalence of familial clustering of IBD among CD patients in China may suggest that the etiology of CD in Chinese population is to a lesser extent attributed to genetic background or family-shared environment compared with the US population. Despite the potential difference in etiology, CD patients from China were as likely to have a history of ileal involvement or have a history of surgery for IBD.
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COMMENTS
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Background
----------

Family history of inflammatory bowel disease (IBD) is the strongest risk factor for developing Crohn's disease (CD) among Western population, and it is also potentially associated with higher probability of having ileal involvement and demand for surgical treatment for CD. However, the prevalence of IBD family history and its role in CD among Asian population has not been well studied.

Research frontiers
------------------

CD has a complex and multifactorial etiology. The roles of and interactions among genetic background, gut microbiota, diet, and autoimmunity are at the frontiers of research. Although the incidence rate of CD in Asian countries is relatively low compared with Western countries, CD incidence is increasing. This epidemiological change gives us a unique opportunity to explore the driving factors of the disease, which could increase the authors understanding of CD and ultimately lead to novel therapeutics.

Innovations and breakthroughs
-----------------------------

Few studies compare family history and disease outcomes of Western and Asian CD patients. The few available studies are mostly based on chart review of patients' medical records from different countries and in different settings, which may be biased by the level of detail recorded within the different medical systems. The current study is innovative in that CD patients from China and United States were investigated with the same survey during the same time period Patients reported information on family history and smoking history themselves, rather than relying on medical notes.

Applications
------------

The results of this study suggest lower prevalence of IBD familial clustering among CD patients in China as compared with the United States. This may suggest that the etiology of CD in Chinese population is to a lesser extent attributed to genetic background or family-shared environment compared with the United States population. Despite the potential difference in etiology, CD patients from China were just as likely to have a history of ileal involvement or have a history of IBD-related surgery as those from United States.

Terminology
-----------

CD is a form of IBD, featured by chronic inflammation, most frequently affecting the terminal ileum and colon, but can also involve other portions of the gastrointestinal tract from mouth to anus.

Peer-review
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In the presented study the differences in family history and clinical outcomes among individuals residing in China and the United States were investigated with a survey-based cross-sectional study. The prevalence of IBD family history was significantly lower in China. It will be interesting to see if the results change as the Chinese study population is studied for a longer period of time, including both longer follow-up of the Chinese population and a larger sample size.

Supported by (in part) Johns Hopkins Institute for Clinical and Translational Research, No. UL1TR001079.

Institutional review board statement: The study was reviewed and approved by the Institutional Review Boards at Johns Hopkins Medicine and the Institutional Review Boards at the Sixth Affiliated Hospital of Sun Yat-sen University.

Informed consent statement: All study participants provided consent.

Conflict-of-interest statement: There are no conflicts of interest to report.

Data sharing statement: No additional data are available.

Manuscript source: Invited manuscript

Specialty Type: Gastroenterology and Hepatology

Country of Origin: United States

Peer-Review Report Classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

Peer-review started: June 12, 2016

First decision: July 20, 2016

Article in press: September 15, 2016

P- Reviewer: Ozen H, Vradelis S S- Editor: Gong ZM L- Editor: A E- Editor: Lu YJ

[^1]: Author contributions: Wang PQ participated in study design, analyzed and interpreted the data, and drafted the initial manuscript; Hutfless S as the principle investigator, supervised and advised the study; Hu J, Al Kazzi ES, Akhuemonkhan E, Zhi M, Gao X, de Paula Pessoa RH, Ghazaleh S, Cornelius T, Sabunwala SA, Ghadermarzi S and Tripathi K participated in recruitment of study participants; all authors participated in reviewing and revising the manuscript.

    Correspondence to: Susan Hutfless, PhD, Assistant Professor, Director, Department of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins University, 600 N Wolfe Street, Blalock 449, Baltimore, MD 21287, United States. <shutfle1@jhmi.edu>

    Telephone: +1-410-5020194
